Login to Your Account



Chi-Med botanical sees defeat in phase III for UC; pipeline hopes remain

By Shannon Ellis
Staff Writer

Wednesday, August 27, 2014

SHANGHAI – Hutchison China Meditech Ltd., also known as Chi-Med, said this month that phase III trials would be terminated for its lead candidate, HMPL-004, a botanical treatment for ulcerative colitis (UC).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription